How would you manage adjuvant therapy in a BRCA1-mutated woman with ER+, Her2 negative breast cancer with residual disease at surgery after neoadjuvant therapy with a taxane-based regimen?

Could carboplatin be considered here? Or any evidence for a PARP inhibitor?

Answer from: Medical Oncologist at Academic Institution

There are several factors to consider in this case. One is whether the patient has received optimum chemotherapy. If there is only minimum residual disease at surgery, I would not recommend additional chemotherapy in the adjuvant setting. On the other hand, if there was signific...

Comments

Medical Oncologist at Huntsman Cancer Institute, University of Utah
Would you offer adjuvant capecitabine if patient h...

Medical Oncologist at Los Angeles VA Medical Center
To call readers attention, we do have similar ques...

Please select the option that best describes you:

How would you manage adjuvant therapy in a BRCA1-mutated woman with ER+, Her2 negative breast cancer with residual disease at surgery after neoadjuvant therapy with a taxane-based regimen?

Related Questions